Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
University of California, Los Angeles · Duke University · +1 more institution
Abstract
PURPOSE: Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL). Three randomized clinical studies have evaluated bevacizumab in combination with FU/LV alone. A combined analysis of raw data from these studies was performed to better assess the efficacy of bevacizumab with FU/LV. PATIENTS AND METHODS: The analysis used primary efficacy data from three independent studies, including 241 patients in a combined control…
Citation impact
- FWCI
- 28.52
- Percentile
- 100%
- References
- 27
Authors
6- FFFairooz F. Kabbinavar
University of California, Los Angeles, Duke University, University of California, San Francisco
- JHJulie Hambleton
University of California, Los Angeles, Duke University, University of California, San Francisco
- RMR. Mass
University of California, Los Angeles, Duke University, University of California, San Francisco
- HIHerbert I. Hurwitz
University of California, Los Angeles, Duke University, University of California, San Francisco
- EKEmily K. Bergsland
University of California, Los Angeles, Duke University, University of California, San Francisco
Topics & keywords
- Bevacizumab
- Medicine
- Irinotecan
- Colorectal cancer
- Internal medicine
- Fluorouracil
- Hazard ratio
- Oncology
- Good health and well-being